The Phase 2 evaluation covered PF-07872412’s four-dose regimen and recorded immune responses for the full set of 25 pneumococcal serotypes targeted by the candidate.
The study also reported on the candidate’s safety and tolerability.
Health
Add as a preferred source on GooglePhase 2 Trial Reports Responses Across 25 Pneumococcal Serotypes for PF-07872412
The study also reported on the candidate’s safety and tolerability.
Updated 1 min read
Related articles
Health
Johnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer Trial
At 50 mg once daily, 24 of 31 evaluable patients had a confirmed PSA decline of at least 50%; a separate imaging group had 11 responses among 16 patients.
Health
Study Links Apalutamide Before and After Surgery to Lower Event Hazard
At three years, 63% of patients on the regimen remained event-free, compared with 41.4% after surgery alone; overall-survival results are not yet available.
Health
Trial Links Darolutamide Add-On to 95% Four-Year Metastasis-Free Survival
The placebo group had an 88% rate at four years. Longer-term follow-up, including overall survival, is continuing.